SynthesisFrontiers in immunology2026
Global development of bispecific antibodies in oncology: a bibliometric analysis of geographic disparities, collaborative models, and emerging translational strategies.
Synthesis in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bispecific antibodies (bsAbs) have rapidly emerged as one of the most promising therapeutic strategies in oncology because of their ability to simultaneously engage multiple molecular targets and enhance antitumor immunity. Although the number of publications has increased substantially, a comprehensive bibliometric characterization of the global research landscape and its developmental trajectory remain lacking. Methods: A bibliometric analysis was conducted using publications retrieved from the Web of Science Core Collection and Scopus from January 2014 to July 2026. After data standardization and deduplication, 5,929 eligible publications were included. CiteSpace, VOSviewer, and Bibliometrix were applied to evaluate publication trends, collaborations among countries, institutions, and authors, influential journals, keyword co-occurrence, citation bursts, and thematic evolution. Results: Global publications on bsAbs demonstrated sustained growth, particularly after 2018, reflecting rapidly increasing scientific interest. The USA and China contributed the largest research outputs, while several internationally collaborative institutions served as major research hubs. Highly cited journals and influential authors formed interconnected knowledge networks that characterized the scholarly structure of the field. Keyword clustering and timeline analyses revealed a progressive transition from antibody engineering and T-cell engager technologies toward clinical applications involving hematologic malignancies, solid tumors, combination immunotherapy, tumor microenvironment, and emerging therapeutic targets. Citation burst analyses further identified evolving research hotspots and highlighted increasing attention to translational and clinically oriented studies. Conclusion: This study reconstructs the global intellectual landscape and thematic evolution of oncology-oriented bsAb research. The findings provide a bibliometric overview of scientific development, identify current research frontiers, and may inform future collaboration, research prioritization, and investigation of next-generation bsAb therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.